VivoSeq
Other

Neurogenic Bladder

12

Pipeline Programs↗

3

Active Trials↗

8

Companies Involved↗

Neurogenic bladder is an emerging landscape with 12 programs across 8 companies. The most active players are Bayer, Vitae Pharmaceuticals Inc., an Allergan affiliate, Astellas. 6 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

40/100

Pipeline Velocity

11/100

Mech. Concentration

13/100

Completion Rate

90/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 2V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 3Astellas logo

Astellas

3 programs

Phase 3Pfizer logo

Pfizer

2 programs

ApprovedAbbVie logo

AbbVie

1 program

ApprovedA

Advanz Pharma

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

15

clinical trials

Completed9 · 60%
Not yet recruiting2 · 13%
Unknown status2 · 13%
Recruiting1 · 7%
Terminated1 · 7%

Clinical Trials

Trial Activity

15 trials

Antibiotic Prophylaxis for Neurogenic Bladder Botox
Recruiting·UUniversity of Alberta·Phase 2·NCT04791579·160 enrolled
Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction
Not yet recruiting·—·Phase 3·NCT07027020·60 enrolled
Noninvasive Electrical Stimulation Device to Improve Bladder Control for Men With Spinal Core Injury
Not yet recruiting·VVA Office of Research and Development·Preclinical·NCT07668063·12 enrolled
Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
Completed·AbbVie logoAbbVie·Phase 4·NCT01192568·52 enrolled
Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease
Completed·SStanford University·Phase 4·NCT01421719·20 enrolled
Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2/3·NCT00796614·231 enrolled
PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT00340704·143 enrolled
Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder
Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 3·NCT01716624·20 enrolled
Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT03612401·20 enrolled
Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods)
Completed·BBuckinghamshire Healthcare NHS Trust·Phase 2·NCT02591901·48 enrolled
Colonizing Neurogenic Bladders With Benign Flora
Completed·US Department of Veterans Affairs·Phase 1·NCT00371631·13 enrolled
Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder
Completed·JJW Pharmaceutical·Phase 4·NCT01228370·95 enrolled
Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients
Terminated·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2/3·NCT02044510·32 enrolled
Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele
Unknown status·UUniversity of Aarhus·Phase 4·NCT00175123·30 enrolled
Can Probiotics be Used in the Prevention of Recurrent UTI in Paediatric Neurogenic Bladder
Unknown status·LLondon Health Sciences Centre·Phase 1/2·NCT02044965·36 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)